BlackRock Fund Advisors recently announced the acquisition of new stake in ADMA Biologics Inc. (NASDAQ:ADMA). The institutional investor has increased its shareholding in the Healthcare company by 18.63% to 13.49 million shares with purchase of 2.12 million shares. This fresh investment now brings its stake to 6.19% valued currently at $47.88 million. In addition, Perceptive Advisors LLC raised its holdings by 0.97 million to 11.9 million shares. And SSgA Funds Management, Inc. has lifted its position by 16.81% or 1.58 million shares – to 11.01 million shares.
With over 3.58 million ADMA Biologics Inc. (ADMA) shares trading Friday and a closing price of $3.09 on the day, the dollar volume was approximately $11.07 million. The shares have shown a positive half year performance of 8.04% and its price on 03/10/23 lost nearly -5.79%. Currently, there are 196.38M common shares owned by the public and among those 176.84M shares have been available to trade.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 4 analysts who have offered their price forecasts for ADMA have a consensus price objective of $5.13. The analysts have set the share’s price value over the next 12 months at a high of $6.00 and a low of $4.50. The average price target is 39.65% above its recent price level and an upside to the estimated low will see the stock gain 31.33% over that period. But an upside of 48.5% will see the stock hit the forecast high price target while median target price for the stock is $5.00.
Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 3 of these insider trades were purchases, accounting for 36,958 shares. Insider sales of the common stock occurred on 7 occasions, with total insider shares sold totaling 551,546 shares.
The top 3 mutual fund holders in ADMA Biologics Inc. are SPDR S&P Biotech ETF, Vanguard Total Stock Market Index, and iShares Russell 2000 ETF. SPDR S&P Biotech ETF owns 6.65 million shares of the company’s stock, all valued at over $23.61 million. The company sold 59100.0 shares recently to bring their total holdings to about 3.06% of the shares outstanding. iShares Russell 2000 ETF sold 12870.0 shares to bring its total holdings to over 4.07 million shares at a value of $14.44 million. iShares Russell 2000 ETF now owns shares totaling to 1.87% of the shares outstanding.
Shares of ADMA Biologics Inc. (NASDAQ: ADMA) opened at $3.30, up $0.02 from a prior closing price of $3.28. However, the script later moved the day high at 3.3000, down -5.79%. The company’s stock has a 5-day price change of -9.65% and -10.43% over the past three months. ADMA shares are trading -20.36% year to date (YTD), with the 12-month market performance up to 76.57% higher. It has a 12-month low price of $1.43 and touched a high of $3.98 over the same period. ADMA has an average intraday trading volume of 2.57 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.69%, -13.51%, and 9.20% respectively.
Institutional ownership of ADMA Biologics Inc. (NASDAQ: ADMA) shares accounts for 67.30% of the company’s 196.38M shares outstanding. Mutual fund holders own 25.23%, while other institutional holders and individual stakeholders account for 46.79% and 23.56% respectively.
It has a market capitalization of $714.19M and a beta (3y monthly) value of 0.93. The earnings-per-share (ttm) stands at -$0.36. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.42% over the week and 4.13% over the month.
Analysts forecast that ADMA Biologics Inc. (ADMA) will achieve an EPS of -$0.06 for the current quarter, -$0.06 for the next quarter and -$0.19 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.09 while analysts give the company a high EPS estimate of -$0.03. Comparatively, EPS for the current quarter was -$0.09 a year ago. Earnings per share for the fiscal year are expected to increase by 41.60%, and 40.60% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate ADMA Biologics Inc. (ADMA) as a “Strong Buy” at a consensus score of 1.70. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 0 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ADMA, a number of firms have released research notes about the stock. Mizuho stated their Buy rating for the stock in a research note on October 13, 2022, with the firm’s price target at $5. Raymond James coverage for the ADMA Biologics Inc. (ADMA) stock in a research note released on November 11, 2021 offered a Strong Buy rating with a price target of $5. Cantor Fitzgerald was of a view on November 09, 2021 that the stock is Overweight, while Jefferies gave the stock Buy rating on June 04, 2019, issuing a price target of $8. H.C. Wainwright on their part issued Buy rating on April 15, 2019.
